Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.

Introduction: Psoriasis is a chronic inflammatory condition that can significantly impact the quality of life (QoL), regardless of the level of skin involvement. Apremilast is indicated for the treatment of moderate to severe psoriasis. Real-world data regarding the impact of apremilast on patient-reported outcomes in clinical practice in the Netherlands is lacking.

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.

Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily practice.

Toxic dermatitis in patients treated with Taxotere® (docetaxel): three case reports.

Three out of 25 patients receiving the same batch docetaxel, developed toxic dermatitis within 5 days after administration. Timing of occurrence was equal and symptoms were similar. Two patients continued with docetaxel without any problems.

Acantholytic dyskeratotic epidermal naevus in a patient with guttate psoriasis on PUVA therapy.

A 79-year-old male with psoriasis developed a zosteriform acantholytic dyskeratotic epidermal naevus during PUVA therapy. The eruption was successfully treated with etretinate 0.75 mg/kg/day and a subsequent course of PUVA with the affected area covered prevented a recurrence of the naevus.